Cytotoxicity analysis of novel monoclonal antibodies targeting SSAT-1
Cancer is one of the leading causes of death worldwide with approximately 8 million deaths in 2010. Most cancer treatments lack specificity and affect the whole body, with toxic effects on both cancerous and normal cells. The cytotoxic effect of a new therapy developed by Biomark Technologies, Inc. targeting cancer cells will be assessed. Biomark Technologies Inc. has found that the expression levels of the gene coding for the protein SSAT 1 is upregulated in cancer cells. The inhibition of this protein is detrimental for the survival of cancer cells, making it an attractive target for cancer treatment. In this proposal we aim to determine the cytotoxic effects in cancer cells when the target is neutralized.